This clinical trial is focused on studying the effects of a new treatment for Rheumatoid Arthritis, a condition that causes pain and swelling in the joints. The treatment being tested is a medication called LY3871801, which is taken in the form of a tablet. The study will compare the effects of LY3871801 to a placebo, which looks like the medication but does not contain the active ingredient.

The purpose of the study is to evaluate how well LY3871801 works in reducing the symptoms of rheumatoid arthritis. Participants in the study will be randomly assigned to receive either LY3871801 or a placebo. The study is designed to be “double-blind,” meaning neither the participants nor the researchers will know who is receiving the actual medication and who is receiving the placebo. This helps ensure that the results are not influenced by expectations about the treatment.

The study will take place over a period of up to 24 weeks. During this time, participants will have regular check-ups to monitor their health and the effects of the treatment. The main goal is to see if LY3871801 can help reduce the activity of the disease, as measured by specific health indicators. Participants will be closely monitored to ensure their safety throughout the study.